Short-term Safety of Dimethyl Fumarate for Psoriasis in Korea.
作者信息
Kim Tae Min, Jo Seong Jin
机构信息
Department of Dermatology, Seoul National University Hospital, Seoul, Korea.
Skin Cancer/Chemotherapy Skin Care Center, Seoul National University Cancer Hospital, Seoul, Korea.
出版信息
Ann Dermatol. 2024 Aug;36(4):252-254. doi: 10.5021/ad.23.054.
Abstract
摘要
相似文献
1
Short-term Safety of Dimethyl Fumarate for Psoriasis in Korea.富马酸二甲酯在韩国治疗银屑病的短期安全性
Ann Dermatol. 2024 Aug;36(4):252-254. doi: 10.5021/ad.23.054.
2
Dimethyl fumarate is efficacious in severe plaque psoriasis : Post hoc analysis from the BRIDGE trial in Austria.富马酸二甲酯对严重斑块状银屑病有效：来自奥地利 BRIDGE 试验的事后分析。
Wien Klin Wochenschr. 2019 Oct;131(19-20):485-492. doi: 10.1007/s00508-019-01551-6. Epub 2019 Oct 7.
3
The Role of Glutathione-S Transferase in Psoriasis and Associated Comorbidities and the Effect of Dimethyl Fumarate in This Pathway.谷胱甘肽-S转移酶在银屑病及其相关合并症中的作用以及富马酸二甲酯在该途径中的作用。
Front Med (Lausanne). 2022 Feb 8;9:760852. doi: 10.3389/fmed.2022.760852. eCollection 2022.
4
Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis.司库奇尤单抗与富马酸二甲酯联合治疗一名银屑病患者及近期诊断为多发性硬化症的病例
Dermatol Ther. 2020 Nov;33(6):e13943. doi: 10.1111/dth.13943. Epub 2020 Jul 14.
5
Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.富马酸二甲酯：中重度斑块状银屑病的治疗药物评价。
Drugs. 2018 Jan;78(1):123-130. doi: 10.1007/s40265-017-0854-6.
6
A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis.评估富马酸二甲酯在中重度银屑病中的安全性。
Expert Opin Drug Saf. 2020 Apr;19(4):373-380. doi: 10.1080/14740338.2020.1736553. Epub 2020 Mar 11.
7
Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.富马酸二甲酯（DMF）与富马酸单乙酯（MEF）盐治疗斑块状银屑病的临床数据比较。
Arch Dermatol Res. 2018 Aug;310(6):475-483. doi: 10.1007/s00403-018-1825-9. Epub 2018 Mar 24.
8
Dimethyl fumarate for psoriasis.用于治疗银屑病的富马酸二甲酯。
Drug Ther Bull. 2017 Dec;55(12):141-144. doi: 10.1136/dtb.2017.12.0565.
9
Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study.富马酸替吡酰胺（PPC - 06）缓释片治疗中重度斑块状银屑病患者：随机、双盲、安慰剂对照的AFFIRM研究的安全性和有效性结果
J Clin Aesthet Dermatol. 2022 Jan;15(1):53-58.
10
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.在中重度斑块型银屑病中使用富马酸二甲酯的临床应用：欧洲专家共识。
J Eur Acad Dermatol Venereol. 2018 Oct;32 Suppl 3:3-14. doi: 10.1111/jdv.15218. Epub 2018 Sep 20.
本文引用的文献
1
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study.富马酸二甲酯治疗中重度斑块状银屑病患者的疗效和安全性：DIMESKIN-2，一项多中心单臂IIIb期研究。
J Clin Med. 2022 Aug 16;11(16):4778. doi: 10.3390/jcm11164778.
2
Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real-world clinical experience.富马酸二甲酯与银屑病传统疗法相比的疗效和安全性：一项意大利真实世界临床经验
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e534-e537. doi: 10.1111/jdv.17997. Epub 2022 Feb 25.
3
Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.生物疗法治疗中重度斑块状银屑病的短期疗效：系统文献综述与增强型多项网络荟萃分析
Dermatol Ther (Heidelb). 2021 Dec;11(6):1965-1998. doi: 10.1007/s13555-021-00602-z. Epub 2021 Sep 22.
4
Dimethyl fumarate treatment for psoriasis in a real-life setting: A multicentric retrospective study.在真实环境下用富马酸二甲酯治疗银屑病：一项多中心回顾性研究。
Dermatol Ther. 2021 Sep;34(5):e15066. doi: 10.1111/dth.15066. Epub 2021 Aug 2.
5
Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis.富马酸二甲酯滴定法用于中重度斑块状银屑病的全身治疗。
Drugs Context. 2021 May 31;10. doi: 10.7573/dic.2020-12-4. eCollection 2021.
6
No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter.未发现富马酸二甲酯（DMF）及其主要代谢物单甲基富马酸（MMF）与人细胞色素 P450（CYP）酶和 P-糖蛋白（P-gp）药物转运体的相互作用证据。
Pharmacol Res Perspect. 2019 Dec 2;7(6):e00540. doi: 10.1002/prp2.540. eCollection 2019 Dec.
7
Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.在中重度斑块型银屑病中使用富马酸二甲酯的临床应用：欧洲专家共识。
J Eur Acad Dermatol Venereol. 2018 Oct;32 Suppl 3:3-14. doi: 10.1111/jdv.15218. Epub 2018 Sep 20.
8
Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.复发缓解型多发性硬化症的疾病修正治疗：网状荟萃分析。
CNS Drugs. 2018 Sep;32(9):813-826. doi: 10.1007/s40263-018-0541-5.
9
Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.在银屑病患者中，富马酸酯类药物的长期真实世界安全性和有效性：一项单中心、回顾性、观察性研究。
J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1710-1727. doi: 10.1111/jdv.15019. Epub 2018 May 18.
10
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm - and placebo-controlled trial (BRIDGE).LAS41008（富马酸二甲酯）治疗成人中重度慢性斑块型银屑病的疗效和安全性：一项随机、双盲、富马酸二甲酯和安慰剂对照试验（BRIDGE）。
Br J Dermatol. 2017 Mar;176(3):615-623. doi: 10.1111/bjd.14947. Epub 2016 Nov 15.
Zotero 插件